Novartis Ag (NVS) Exchange Rate Effect (2009 - 2026)
Novartis Ag (NVS) posted Exchange Rate Effect of -$18.0 million for Q2 2026, up 76.62% sequentially from -$77.0 million in Q1 2026, and down 104.71% YoY from $382.0 million in Q2 2025.
Novartis Ag (NVS) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Novartis Ag has reported Exchange Rate Effect for 18 years, with the latest figure at -$18.0 million in Q2 2026.
- Quarterly Exchange Rate Effect fell 104.71% year-over-year to -$18.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$81.0 million (down 119.1% YoY) and the FY2025 annual result came in at $576.0 million, up 293.29% from the prior year.
- Exchange Rate Effect improved to -$18.0 million in Q2 2026 per NVS's latest filing, from -$77.0 million in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $382.0 million in Q2 2025 and troughed at -$314.0 million in Q4 2024.
- A 5-year average of $13.9 million and a median of -$20.0 million in 2025 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2024 and 2025: Exchange Rate Effect plunged 3300.0% in 2024, then surged 1223.53% in 2025.
- Over 5 years, Exchange Rate Effect stood at $141.0 million in 2022, then rose by 13.48% to $160.0 million in 2023, then slumped by 296.25% to -$314.0 million in 2024, then jumped by 111.46% to $36.0 million in 2025, then slumped by 150.0% to -$18.0 million in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$18.0 million, -$77.0 million, and $36.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.69 Bn | 631.94 Bn | 17.26 Bn | 5.00 Mn |
| 2 | AbbVie | 469.96 Bn | 463.39 Bn | 12.70 Bn | -7.00 Mn |
| 3 | Merck | 375.18 Bn | 368.04 Bn | 12.21 Bn | -37.00 Mn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn | -18.00 Mn |
| 5 | Astrazeneca | 257.49 Bn | 252.59 Bn | 12.86 Bn | 9.00 Mn |
| 6 | Amgen | 236.49 Bn | 222.50 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.35 Bn | 179.17 Bn | 6.22 Bn | -19.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -4.00 Mn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn | 11.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.00 Mn |
| Jun 30, 2026 | -18.00 Mn |
| Mar 31, 2026 | -77.00 Mn |
| Mar 31, 2026 | -77.00 Mn |
| Dec 31, 2025 | 36.00 Mn |
| Dec 31, 2025 | 36.00 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | 382.00 Mn |
| Jun 30, 2025 | 382.00 Mn |
| Mar 31, 2025 | 180.00 Mn |
| Mar 31, 2025 | 180.00 Mn |
| Dec 31, 2024 | -314.00 Mn |
| Dec 31, 2024 | -314.00 Mn |
| Sep 30, 2024 | 176.00 Mn |
| Sep 30, 2024 | 176.00 Mn |
| Jun 30, 2024 | -34.00 Mn |
| Jun 30, 2024 | -34.00 Mn |
| Mar 31, 2024 | -126.00 Mn |
| Mar 31, 2024 | -126.00 Mn |